Cited by

• Immunotherapy strategy of EGFR mutant lung cancer.

  Yu S, Liu D, Shen B, Shi M, Feng J. Yu S, et al. Am J Cancer Res. 2018 Oct 1;8(10):2106-2115. eCollection 2018. Am J Cancer Res. 2018. PMID: 30416860 Free PMC article.
• [Lung cancer : What has been confirmed in therapy?].

  Heigener DF, Reck M. Heigener DF, et al. Internist (Berl). 2017 Dec;58(12):1258-1263. doi: 10.1007/s00108-017-0339-4. Internist (Berl). 2017. PMID: 29043377 Review. German.
• Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade.

  Chi A, He X, Hou L, Nguyen NP, Zhu G, Cameron RB, Lee JM. Chi A, et al. Cancers (Basel). 2021 Jun 11;13(12):2924. doi: 10.3390/cancers13122924. Cancers (Basel). 2021. PMID: 34208113 Free PMC article. Review.
• Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.

  Singh PK, Kumar R, Bal A, Gupta N, Kapoor R, Prasad KT, Singh N. Singh PK, et al. JCO Glob Oncol. 2020 Feb;6:174-179. doi: 10.1200/JGO.19.00357. JCO Glob Oncol. 2020. PMID: 32031456 Free PMC article. No abstract available.
• The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.

  Jiang M, Fares AF, Shepshelovich D, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz AG, Tardon A, Shete S, Schabath MB, Teare MD, Le Marchand L, Zhang ZF, Field JK, Brenner H, Diao N, Xie J, Kohno T, Harris CC, Wenzlaff AS, Fernandez-Tardon G, Ye Y, Taylor F, Wilkens LR, Davies M, Liu Y, Barnett MJ, Goodman GE, Morgenstern H, Holleczek B, Thomas S, Brown MC, Hung RJ, Xu W, Liu G. Jiang M, et al. Lung Cancer. 2021 Feb;152:58-65. doi: 10.1016/j.lungcan.2020.11.029. Epub 2020 Dec 4. Lung Cancer. 2021. PMID: 33352384 Free PMC article.